PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

Zeitschrift fur Epileptologie is a vital resource in the field of neurology and pediatric healthcare, published by Springer Heidelberg. With its ISSN 1617-6782 and E-ISSN 1610-0646, the journal focuses on the latest research and clinical practices pertaining to epilepsy, catering to an audience that includes researchers, clinicians, and students. Although it currently holds a Q4 ranking in both Neurology (clinical) and Pediatrics categories, the journal's commitment to disseminating key findings and enhancing understanding in these fields positions it as an important contributor to ongoing discussions around epilepsy management and child health. The journal has published continuously from 2005 to 2022, offering both traditional and open-access viewing options that increase its accessibility to a global audience. By maintaining an emphasis on high-quality research, Zeitschrift fur Epileptologie strives to improve patient care and embrace innovations in treatment methodologies.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Annals of Indian Psychiatry is a premier journal dedicated to the field of mental health and psychiatry, published by Wolters Kluwer Medknow Publications. As an Open Access journal since 2017, it provides a platform for disseminating high-quality research articles, clinical studies, and reviews that address the diverse aspects of psychiatric disorders, treatment methodologies, and mental health policy in India and beyond. The journal aims to bridge gaps in the existing literature, support practitioners with evidence-based insights, and foster dialog among researchers in the psychiatric community. With an emphasis on innovative approaches and culturally relevant practices, the Annals of Indian Psychiatry serves as a vital resource for psychiatrists, psychologists, social workers, and students engaged in clinical practice and academic research. Its commitment to improving mental health outcomes in diverse populations makes it a significant contributor to the global discourse on psychiatric health.

Psychiatria Polska is a distinguished journal published by WYDAWNICZY POLSKIEGO TOWARZYSTWA, focused on advancing the field of psychiatry and mental health. Established in 1967, this journal has become a vital resource for researchers, clinicians, and students, contributing to the understanding of psychiatric disorders and their treatments. With an ISSN of 0033-2674, it features a diverse range of studies, case reports, and reviews, making it an essential platform for sharing innovative findings within the psychiatric community. Although currently categorized in the Q3 quartile for both Medicine (miscellaneous) and Psychiatry and Mental Health in 2023, its increasing impact is evidenced by its Scopus ranking of #345 out of 567 in its category, placing it in the 39th percentile. Located in Cracow, Poland, Psychiatria Polska continues to foster international collaboration and knowledge exchange, despite being non-open access, ensuring that its high-quality content reaches a wide audience. This journal is dedicated to enhancing the dialogue on mental health, making it an indispensable resource for those committed to improving psychiatric practice and research.

Frontiers in Psychiatry is a leading journal dedicated to advancing research within the field of psychiatry and mental health. Published by FRONTIERS MEDIA SA, the journal has established a commendable reputation since its inception, reflected in its Q1 status in the 2023 Psychiatry and Mental Health category and a robust ranking of 142 out of 567 in the Scopus database. With an open access model initiated in 2009, Frontiers in Psychiatry aims to disseminate high-quality research to a global audience, fostering collaboration and innovation among researchers, clinicians, and students alike. The journal covers a broad spectrum of topics, including neurobiology, psychosocial factors, treatments, and public health implications of mental disorders, ensuring comprehensive representation of contemporary psychiatric science. Located in Lausanne, Switzerland, and running until 2024, the journal not only emphasizes the importance of mental health research but also encourages interdisciplinary discourse, making it an essential resource for anyone invested in the well-being of individuals and communities alike.

Journal of Psychiatric Research, published by Pergamon-Elsevier Science Ltd, is a premier academic journal dedicated to advancing our understanding of psychiatric disorders and mental health. With its ISSN 0022-3956 and E-ISSN 1879-1379, the journal has established a significant presence in the field, reflected in its impressive Q1 ranking in both Biological Psychiatry and Psychiatry and Mental Health as of 2023. Nestled in the heart of the United Kingdom, the journal has been fostering scholarly discourse since its inception in 1961, with publication horizons extending to 2024. As an authoritative source of empirical research, the journal attracts a global readership, providing vital insights that inform clinical practices and policies. It holds a respectable rank of #103 out of 567 in Medicine and Psychiatry and Mental Health, with an 81st percentile ranking, underscoring its influence in shaping psychiatric research. Although it does not offer open access, the journal is dedicated to disseminating critical knowledge that enables researchers, clinicians, and students to address the complexities of mental health challenges effectively. For those engaged in psychiatric studies, the Journal of Psychiatric Research remains an indispensable resource.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE is a distinguished publication in the field of Psychiatry and Mental Health, published by TAYLOR & FRANCIS LTD in the United Kingdom. With an impressive 2023 impact factor that places it in the Q2 category among its peers, this journal is an essential resource for researchers, clinicians, and students dedicated to advancing mental health practices and understanding psychiatric disorders. Covering topics from clinical studies to innovative treatment methodologies, the journal welcomes original research, reviews, and case studies that contribute valuable insights into clinical practice. Accessible without any open access restrictions, the journal has been a pivotal platform since its inception in 1997, facilitating knowledge exchange in the field up to 2024. As evidenced by its notable Scopus ranking within the top 73rd percentile of Psychiatry and Mental Health, it remains committed to impacting clinical practices significantly.

NEUROPSYCHOBIOLOGY, published by KARGER, is a leading academic journal that has been at the forefront of exploring the intricate relationships between neuroscience and psychological processes since its inception in 1975. With both an ISSN of 0302-282X and an E-ISSN of 1423-0224, the journal is renowned for its rigorous peer-reviewed articles and significant contributions to the fields of Biological Psychiatry, Neuropsychology, and Physiological Psychology. Its impact is reflected in its esteemed Scopus rankings, standing out in the 92nd and 81st percentiles in their respective categories. With a commitment to advancing understanding in mental health and neurological science, NEUROPSYCHOBIOLOGY is classified in the Q3 and Q1 quartiles, making it a vital resource for researchers, clinicians, and students alike. Based in Switzerland, the journal embraces a holistic approach to psychological research, bridging gaps between theoretical frameworks and practical applications, thus promoting impactful advancements in the understanding of the human mind.
Explore the latest findings and theories with NEUROPSYCHOBIOLOGY, where your work can contribute to the evolving landscape of neuropsychological studies.

NPJ Schizophrenia is a premier open-access journal published by NATURE PORTFOLIO, dedicated to advancing the field of psychiatric research with a focus on schizophrenia and related mental health disorders. Since its inception in 2015, the journal has established itself as a leading platform for disseminating high-quality research, reflected in its impressive 2023 impact metrics: Q1 rankings in Biological Psychiatry, Clinical Psychology, and Psychiatry and Mental Health. With its global reach and rigorous peer-review process, NPJ Schizophrenia fosters collaboration among researchers, clinicians, and policymakers, enhancing understanding and treatment of this complex condition. The journal is available to a worldwide audience, promoting accessibility to vital information that shapes future research and clinical practices. Engaging with NPJ Schizophrenia means contributing to a pivotal conversation in the mental health field, making it an essential resource for those dedicated to improving patient outcomes.